Introduction
Caveolin was ®rst identi®ed as a major substrate of vsrc that localized to the striated inner surface of 50 ± 100 nm invaginations of the plasma membrane termed caveolae (Glenney and Soppet, 1992; Rothberg et al., 1992) . It was independently identi®ed as VIP-21, a 21 kDa integral membrane component of trans-Golgi network derived vesicles (Kurzchalia et al., 1992) .
Caveolae are believed to be present in most cell types, but are most abundant in terminally dierentiated cells including adipocytes, endothelial cells, type I pneumocytes, and skeletal muscle cells (Fan et al., 1983) .
Caveolin has been implicated as a regulator of a diverse number of intracellular signalling pathways. Puri®ed caveolae membranes are enriched with speci®c lipids (cholesterol and glycosphingolipids (Murata et al., 1995; Fra et al., 1995) ) and a plethora of lipidmodi®ed signalling molecules including H-ras, c-src, other src-like kinases, eNOS, plasminogen activator and heterotrimeric G-proteins Li et al., 1995 Garcia-Cardena, et al., 1996; Stahl and Mueller, 1995) . In addition, a number of membrane associated receptors, including several that are coupled to G-proteins or possess intrinsic tyrosine kinase activity, localize to or are internalized by caveolae (Lisanti et al., 1994) . Caveolae may play an important role in sequestering inactive signalling molecules, and down-regulating receptor activity. Alternatively, caveolae may provide an environment for the regulated activation of these molecules and explain cross-talk between dierent signalling pathways.
Caveolin is one of only a few transformationdependent v-src substrates identi®ed. The functional signi®cance of its phosphorylation is unknown; it may allow binding between caveolin and signalling molecules that contain an SH2-domain. In this regard, caveolin-1 has been found to co-immunoprecipitate with Shc (Wary et al., 1996) . Both tyrosine phosphorylation of caveolin and transformation by v-src depend upon membrane targeting of v-src by N-terminal myristylation (Glenney, 1989) . This has prompted the suggestion that caveolin may be a critical target during cellular transformation (Glenney, 1989) . This hypothesis has been supported by the observation that both caveolin expression and caveolae are reduced in NIH3T3 cells transformed by activated oncogenes other than v-src, including H-ras, v-abl, and bcr-abl. Further, the extent of reduction in the expression of caveolin correlated with the ability of these oncogenically transformed cells to form colonies in soft-agar (Koleske et al., 1995) . Induced expression of caveolin-1 in ras-transformed NIH3T3 cells was shown to abrogate anchorage-independent growth; this was accompanied by inhibition of the ras/raf/MAPK signalling pathway, and by induction of apoptosis (Engelman et al., 1997) . Ectopic expression of Caveolin-1 in human breast tumour-derived cell lines has also been shown to suppress in vitro tumour growth (Lee et al., 1998) . A role for caveolin in anchorage-dependent growth had previously been suggested by the demonstration that it interacts with both integrins and Shc (Wary et al., 1996) , providing a possible link between integrin occupation and the ras/ raf/MAPK signalling pathway.
Recently, a family of caveolin-related proteins have been identi®ed , Tang et al., 1996 and caveolin has been re-named caveolin-1. Here, we report the mapping of the gene encoding Caveolin-1 to human chromosome 7q31, in proximity to the marker D7S522, which has been mapped to q31.1. A number of studies has revealed a high incidence of loss of heterozygosity (LOH) at 7q31 in a broad range of human tumours, including carcinomas of the breast (Bieche et al., 1992; Zenklusen et al., 1994a) , colon (Zenklusen et al., 1995a) , kidney (Shridhar et al., 1997) , ovary (Kerr et al., 1996; Koike et al., 1997; Zenklusen et al., 1995b) , pancreas (Achille et al., 1996) , prostate (Takahashi et al., 1995; Zenklusen et al., 1994b) , and stomach (Kuniyasu et al., 1994) , as well as squamous cell carcinomas of the head and neck (Zenklusen et al., 1995a , Loughran et al., 1997 . The highest frequency of LOH was observed at D7S522. Collectively, these studies implicate the 7q31.1 region as harbouring a multi-tissue tumour suppressor gene. We ®nd no evidence for mutation or epigenetic modi®cation of CAVEOLIN-1 in primary tumours or in tumour-derived cell lines. We demonstrate that Caveolin-1 is not expressed in normal breast ductal epithelial cells, contrary to the claims of other workers (Lee et al., 1998) , but is highly expressed in breast myoepithelial cells. This expression is maintained in myoepithelioma and in myoepithelial hyperplasia. CAVEOLIN-1 is thus unlikely to be the 7q31.1 tumour suppressor gene.
Results
CAVEOLIN-1 maps to a region less than 500 Kbp between the markers D7S522 and WI-455 on human chromosome 7q31.1 A region of human chromosome 7 proximal to the Genethon microsatellite marker D7S522 (125 cM from the p-terminus of human chromosome 7 and corresponding to cytogenetic band 7q31.1) is believed to harbour a multi-tissue tumour suppressor gene. We searched the map of expressed human gene tags (Schuler et al., 1996 ; http://www.ncbi.nlm.nih.gov/cgibin/SCIENCE96/) for transcripts mapping to this chromosomal region in a ®rst bid to identify the tumour suppressor gene.
The expressed sequence tags (ESTs) T57690 and D29206 have been mapped to the genomic intervals between D7S486 and D7S2487 (125 ± 126 cM from 7pter) and D7S523 and D7S486 (123 ± 125 cM from 7pter) respectively, using the Stanford G3 and Genebridge 4 radiation hybrid mapping panels (Schuler et al., 1996) . These adjacent genomic intervals comprise approximately 2 Mbp of¯anking DNA.
We found that both these ESTs corresponded to the 3' untranslated region of CAVEOLIN-1 (GenEMBL accession number Z18951, Swiss-Prot accession number P33724) and so we decided to further re®ne the mapping position of CAVEOLIN-1 by STS content mapping the CEPH megaYAC clones 746h5, 905g2, 921b4 and 976b5. These YAC clones constitute a part of the Whitehead-Genethon YAC STS contig WC7.6 (http://www-genome.wi.mit.edu/) and between them encompass the physical interval between the markers D7S486 and D7S2742 (Figure 1 ). We found that the three clones 746h5, 905g2 and 921b4 were positive for T57690, D29206, as well as an STS corresponding to exon 3 of CAVEOLIN-1 (Figure 1a) . Further, an STS corresponding to exon 1 of CAVEOLIN-1 was present only on YAC clones 746h5 and 921b4, but not 905g2, implying that the genomic insert in this clone ends within the CAVEOLIN-1 locus (Figure 1a) . From the STS content of these YAC clones it is possible to re®ne the mapping position of CAVEOLIN-1 to the interval D7S522-WI-455 (less than 500 Kbp), and to establish that the gene is oriented with its 3'-end towards the telomere.
CAVEOLIN-1 comprises three exons and is associated with a CpG island
A cDNA probe corresponding to the open reading frame of CAVEOLIN-1 was used to probe a human PAC library. One positively hybridizing clone was identi®ed, 162-021. PAC DNA was subcloned and selected inserts sequenced. Comparing the genomic sequence with the published cDNA sequence (GenEMBL Z18951) revealed the exon-intron boundaries of the gene. CAVEOLIN-1 comprises three exons (GenEMBL accession numbers AF095591, AF095592 and AF095593 correspond to exons 1 ± 3 of human CAVEOLIN-1 respectively). It is apparent from the high G/C content of the ®rst two of these exons that CAVEOLIN-1 is associated with a CpG island (Bird, 1986) .
CAVEOLIN-1 is not mutated in tumour cell lines
Based upon sequences¯anking the exons of CAVEO-LIN-1, oligonucleotide primers were synthesized to allow PCR-ampli®cation of the intervening exons in addition to the splice junction sequences (Materials and methods). It was possible to amplify DNA corresponding to exons 1 and 3, but not exon 2. This failure probably results from the high (62.9%) G/C content of this exon. PCR ampli®cation of exon 1 and exon 3 was attempted on DNA from several tumour-derived cell lines (Table 1 ). The presence of sequence alterations was assayed by single strand conformation polymorphism (SSCP) analysis. We found no changes in electrophoretic mobility of ampli®cation products that might indicate an underlying mutation in the sequence (Figure 2 ). The absence of mutations in the entire coding region (including exon 2) of CAVEOLIN-1 was con®rmed for the cell lines A1698, A1698OR, HeLa, MDA-MB-231, OVCAR5, and SUSM-1 by direct sequencing cDNA generated from these cell lines by RT ± PCR (data not shown).
CAVEOLIN-1 is not methylated in primary tumours or tumour-derived cell lines
There have now been several reported instances of genes possessing CpG islands being transcriptionally silenced by methylation during tumour progression, and methylation has been proposed as a possible epigenetic mechanism of tumour suppressor gene inactivation. In the case of CDKN2A, for example, methylation is perhaps the most prevalent mechanism whereby this gene is inactivated in tumours (Herman et al., 1995; Loughran et al., 1996) . Therefore, we decided to look at the methylation status of CAVEOLIN-1 in DNA from several primary ovarian tumours as well as the cell lines previously analysed for mutations in order to determine whether methylation occurred, with what frequency, and whether it correlated with the level of expression of Caveolin.
Genomic DNA samples from 26 primary ovarian tumours and the tumour-derived cell lines in Table 1 were restriction digested with EcoRV/HindIII alone or with EcoRV/HindIII in combination with either HpaII (which has recognition sequence CCGG, but will not cleave DNA if the second cytosine residue is methylated on the 5-position) or MspI (which cleaves DNA at the same sites as HpaII regardless of methylation). Restriction digested DNA was hybridized on a blot with a probe corresponding to exon 1 of CAVEOLIN-1 (Figure 3 and data not shown for cell line DNA samples). In all instances the pattern of hybridization was identical for DNA tracts digested with either HpaII or MspI, indicating that in no instance did exon 1 of CAVEOLIN-1 appear to be methylated.
Levels of expression of CAVEOLIN-1 were determined by RT ± PCR analysis of total RNA and Western blot analysis of protein extracted from the tumourderived cell lines (Figure 4 ). The level of CAVEOLIN-1 expression determined by RT ± PCR analysis correlated with that determined by Western blot analysis in all cases with the exception of the HeLa cell line, where transcript was apparent but no protein was detected, suggesting that expression of CAVEOLIN-1 is regulated primarily at the transcriptional level in the majority of cell types. Presumably, low levels of expression of CAVEOLIN-1 in the cell lines ZR-75, MCF-7, CH1, OVCAR3, OVCAR4, A2780 and COLO357 did not result from transcriptional silencing by methylation, but must be due to other unidenti®ed factors.
Figure 1 (a) STS content mapping of CEPH mega YAC clones 746h5, 905g2, 921b4, and 976b5. PCR assays indicated at the top of the panel were performed on DNA from the monochromosome hybrid cell line A92/Hytk7, which contains a single cytogenetically intact copy of human chromosome 7 (Cuthbert et al., 1995) , YAC clone DNA, and PAC clone 162-O21 DNA. (b) A physical map of the D7S486-D7S2742 genomic interval. The markers shown are derived from a number of sources: STSs from random genomic DNA were largely derived by the National Human Genome Research Institute (http://www.nhgri.nih.gov/DIR/ GTB/CHR7/), and by the Whitehead Institute Centre for Genome Research (http://www-genome.wi.mit.edu/), while information on restriction fragment length polymorphisms (RFLPs) converted in to STSs was obtained from the Genome Database (http:// gdbwww.gdb.org); CA.GT dinucleotide repeat microsatellite markers were derived by Genethon (http://www.genethon.fr/ genethon_en.html); and information on EST-derived STSs was obtained from the human gene map (http:// www.ncbi.nlm.nih.gov/cgibin/SCIENCE96/). The order of markers presented here is based upon mapping information available at various of these electronic sites, and also on STS content mapping of a panel of contiguated cosmid clones spanning this interval (unpublished data) CAVEOLIN-1 is not expressed in normal breast ductal epithelium but is expressed in benign and malignant myoepithelial cells Caveolin-1 was found to be one of 26 gene products down-regulated during mammary tumourigenesis using dierential display to compare RNA populations between breast tumours and normal breast tissue. In addition, expression of Caveolin-1 was found to be absent in several mammary carcinoma-derived cell lines including MT-1, MCF-7, ZR-75-1, T47D, MDA-MB-361 and MDA-MB-474 (Sager et al., 1994) . It has been demonstrated that CAVEOLIN-1 is expressed in cells cultured from normal mammary epithelium (Lee et al., (1998) , and in agreement with Sager et al. (1994) that expression is reduced or undetectable in breast tumourderived cell lines (in this study we also con®rm that MCF-7 and ZR-75-1 do not express detectable levels of Caveolin-1 protein). Further, these authors show that ectopic expression of CAVEOLIN-1 in breast tumourderived cell lines suppresses in vitro growth and colony formation in soft agar. Together these ®ndings suggest that loss of expression of CAVEOLIN-1 contributes to the oncogenic transformation of breast epithelial cells.
To determine which cell types express Caveolin-1 in breast tissue in vivo, and whether expression is altered in cancers, we stained sections of normal breast and breast cancers by indirect peroxidase immunohistochemistry using an anti-Caveolin-1 polyclonal antibody C13630, which has previously been validated for immunochemical detection of Caveolin-1 expression (Lee et al., 1998) . Using this reagent, we failed to detect Caveolin-1 expression within the epithelial cells comprizing normal ducts or terminal ductal lobular units within breast reduction specimens, although strong staining was apparent in myoepithelial cells sheathing the ducts and surrounding ®brous tissue (Figure 5a ). In addition, we found no Caveolin-1 immunolabelling in the invasive carcinoma cells of the primary breast cancers we examined, which were deemed to be of ductal epithelial origin (Figure 5b ). However, Caveolin-1 immunochemical staining was found to be retained in malignant myoepithelial cells (Figure 5c ) and hyperproliferative myoepithelium (Figure 5d ).
Discussion
Caveolin-1 has been implicated in the process of cellular transformation. Signi®cantly, heterologous expression of CAVEOLIN-1 has been shown to suppress ras and v-abl mediated oncogenic transformation of NIH3T3 ®broblasts (Engelman et al., 1997) , and independently the anchorage-independent growth of mammary carcinoma-derived cell lines (Lee et al., 1998) . We have mapped CAVEOLIN-1 to human chromosome 7q31.1, as a candidate for a multi-tissue tumour suppressor gene that has been localized to this subchromosomal region . Like CAVEOLIN-1, this tumour suppressor gene is also conserved in mouse (Zenklusen et al., , 1997 . Incidences of LOH of over 80% have been detected in breast carcinomas (Zenklusen et al., 1994a) , implying that the chromosome 7-tumour suppressor gene is the most frequently inactivated target during breast Lee et al., 1998) . Down-regulation appears to be mediated primarily at the level of transcription (Lee et al., 1998) . Independently, a gene implicated in replicative senescence, the immortality complementation group D gene, has also been mapped to the 7q31.1 chromosomal region (Ogata et al., 1993) , raising the possibility that the tumour suppressor gene and the immortality complementation group D gene are one and the same. Caveolin-1 has been found to associate with the neurotrophin receptor, p75 NTR , which is required for sphingomyelin hydrolysis and ceramide production in neurones and glial cells (Bilderback et al., 1997) . In turn levels of ceramide are increased in senescent cells, and ceramide has been shown to be capable of inducing senescent-like growth arrest in normal human diploid ®broblasts (Venable et al., 1995) , providing a possible link between Caveolin-1 and replicative senescence.
In this study, we found no evidence for micro-scale mutational inactivation of CAVEOLIN-1 by performing SSCP analysis on genomic DNA samples prepared from a number of tumour-derived cell lines (and also by sequencing CAVEOLIN-1 cDNA prepared from a subset of them); nor did we ®nd evidence of any gross alterations or homozygous deletions of the gene by Southern blot analysis (in agreement with Lee et al., 1998) , or of altered gene product by RT ± PCR or Western blot analysis. Further, we found no evidence of epigenetic modi®cation of CAVEOLIN-1 expression by methylation of a CpG island associated with the promoter and ®rst two exons of this gene.
In sections of normal breast tissue we could not detect expression of Caveolin-1 by immunohistochemistry in glandular epithelial cells, which are believed to be the cell type that undergo transformation in the great majority of breast carcinomas, although there was strong Caveolin-1 immunolabelling in myoepithelial and stromal cells. It would be predicted, therefore, that in sections of breast tumours, which have a high content of epithelial cells, less overall Caveolin staining would be apparent, as is indeed evident, and this would explain why CAVEOLIN-1 was found to be downregulated in breast cancers (Sager et al., 1994) . However, it is apparent from the breast cancer derived cell line MDA-MB-231 that at least a subset of breast carcinoma cell lines express CAVEOLIN-1, and from our data we suggest that such cell lines could have originated from myoepithelial cells.
Our ®nding that CAVEOLIN-1 is not expressed in normal breast glandular epithelial cells appears to contradict the ®ndings of Lee et al. (1998) , who demonstrate the presence of Caveolin-1 protein in early passage epithelial cells cultured from normal breast tissue, as well as in immortalized, nontumourigenic, mammary epithelial cells. One possible explanation for this dierence is that in vitro culture conditions may induce CAVEOLIN-1 expression in non-transformed glandular epithelial cells, but not malignant epithelial cells. Certainly, Lee et al. (1998) show that the expression of the a-isoform of Caveolin-1 increases in a cell cycle dependent manner in cultured breast epithelial cells. Thus, we might only expect to detect Caveolin-1 protein in proliferating cells, and a greater fraction of cells will be in cycle in culture compared to in vivo, implying that it will be correspondingly harder to detect CAVEOLIN-1 expression in tissue sections compared to cultured cells. However, we did not detect Caveolin-1 immunochemical staining in any hyperproliferative pre-malignant lesion that we observed, other than in hyperproliferative myoepithelial cells (Figure 5d ), which argues that any dierence in proliferation alone cannot account for the discrepancy in our ®ndings.
An alternative explanation for our dierent ®ndings is that epithelial cells cultured from normal breast do not represent glandular epithelial cells, but may be derived from another cell type, possibly myoepithelial cells, which we show do express abundant Caveolin-1 protein. In this case, the consequence of overexpressing Caveolin-1 in malignant breast epithelial cells, namely growth inhibition, may be less physiologically relevant than ®rst thought, since these cells do not represent an appropriate target cell type. Lee et al. (1998) failed to satisfactorily explain how re-expression of CAVEOLIN-1 in carcinoma cells was at all consequential when it failed to result in de novo caveolae formation, as endocytosis/vesicular transport associated with the function of this protein is believed to be important for its eects on growth (Koleske et al., 1995; Scherer et al., 1995) . Perhaps an ability of Caveolin protein to modulate integrin-mediated growth signalling is more signi®cant than its ability to induce caveolae formation. Lee et al. (1998) also do not compare the growth rate of cultured normal mammary epithelial cells to their transformed counterparts, to give an indication of the eect of physiological levels of the protein on cell growth.
Caveolae are present in many normal cell types, including epithelial cells, and it is still possible that loss of Caveolin expression following methylation of the gene could contribute to carcinogenesis. However, there appears to be no correlation between the presence of wild-type Caveolin-1 and allele loss on chromosome 7 since the cell lines COLO357, MDA-MB-231, OVCAR5, and TMSG all demonstrate chromosome 7 LOH which encompasses the CAVEO-LIN-1 locus (unpublished data), but with the exception of COLO357 express wild-type Caveolin-1. This ®nding has also been extended to a series of head and neck squamous cell carcinoma derived cell lines (unpublished data) that we have established and analysed for allele loss (Loughran et al., 1997) .
The failure to detect`®rst-hit' mutations in CAVEOLIN-1 (either micro-scale alteration or gross deletions and re-arrangements) in any of the cancer cell lines studied here, coupled with the expression of wildtype protein in cells portraying chromosome 7 LOH suggests that this gene is not the target for inactivation by LOH (the`second hit'), which is frequently observed at 7q31 in human solid cancers. Further, there is no correlation between the expression of CAVEOLIN-1 and complementation group status for immortality since the cell lines A1698, A1698OR, MDA-MB-231, OVCAR5, and SUSM-1 are all in immortality complementation group D (Pereira-Smith and Smith, 1988 and unpublished data), but nonetheless express wild-type Caveolin-1. Therefore, despite in vitro ®ndings that Caveolin-1 can function as a suppressor of cellular transformation, we conclude that CAVEO-LIN-1 is not the immortality complementation group D gene, nor is it a target for mutational inactivation during breast tumourigenesis. We cannot, however, formally exclude a role for Caveolin-1 in suppressing cellular transformation in vivo.
Materials and methods

STS content mapping of YACs
Yeast strains containing CEPH megaYAC clones 746h5, 905g2, 921b4 and 976b5 were obtained from Research Genetics, Inc. (Huntsville, USA). Total yeast DNA was prepared from cultures of these strains using a Wizard Genomic DNA kit (Promega, UK), according to the manufacturer's instructions. 100 ng of yeast DNA was subjected to PCR ampli®cation using 1 mM oligonucleotide primers (T57690 L: TTTAAAACAGACACTGGCATGG, R: AGTTTACAGATTGAATCACAAAGCC; D29206 L: TTTAAAACAGACACTGGCATGG, R: AGTTTACA-GATTGAATCACAAAGCC; for exons 1 and 3 see below), 16reaction buer, 1.5 mM MgCl 2 , and 1 m Taq polymerase (Bioline, UK), and 100 mM dNTPs (Promega) in a total reaction volume of 25 ml. The thermal cycling parameters consisted of 30 rounds of 1 min at 948C, 30 s at 558C, and 30 s at 728C using an MJC Research PTC-200 thermal cycler (Genetic Research Instrumentation Ltd., UK). The total PCR ampli®cation product was loaded alongside an aliquot of FX174/HaeIII restriction fragments onto a 2% agarose gel and resolved by electrophoresis. DNA was detected by ethidium bromide staining (5 mg/ml) and UV trans-illumination.
Preparation of a CAVEOLIN-1 cDNA probe An aliquot of double stranded cDNA prepared from normal human ®broblasts was subjected to PCR using the above reaction conditions and 1 mM each of the following oligonucleotide primers L: CATGTCTGGGG-GCAAATACG, R: GAACTTGAAATTGGCACCAGG, which amplify the entire open reading frame of CAVEO-LIN-1.
Screening the human PAC library
Nylon ®lters supporting a total human genomic DNA library (Ioannou et al., 1994) were obtained from the UK MRC Human Genome Mapping Project Resource (UKHGMPR). Filters were pre-hybridized at 658C for 4 h in hybridization buer (56SSPE, 56Denhardt's, 0.5%(w/v) SDS, 1 mg/ml torula yeast RNA type VI), and then hybridized overnight at 658C with 25 ng of CAVEOLIN-1 cDNA probe radiolabelled with 50 mCi of a 32 P-dCTP (Amersham International plc., Amersham, Buckinghamshire, UK) using a random-priming labelling kit (HighPrime; Boehringer Mannheim UK). Filters were washed twice in 0.26SCC/0.1%(w/v) SDS for 30 min at 658C, and then once in 0.16SSC/0.1%(w/v) SDS for a further 30 min at 658C. The ®lters were then exposed to Xray ®lm (X-OMAT-AR, Eastman Kodak Co., USA) overnight at 7708C in a cassette with an intensifying screen. The clone 162-O21 gave a positive hybridization signal and was requested from the UKHGMPR.
Subcloning and sequencing of CAVEOLIN-1
One hundred ng of PAC 162-O21 DNA digested with 10 units each of EcoRI and HindIII (Life Technologies, UK) was ligated with 100 ng of restricted pBluescript (KS+/7) (Stratagene Ltd., UK). One tenth of the ligation reaction was transformed into 100 ml of competent DH5a E. Coli (Life Technologies) which were then plated on agar containing 50 mg/ml ampicillin. Colonies were transferred onto nylon ®lters and hybridized as above with CAVEO-LIN-1 cDNA. Plasmid DNA was prepared from positively hybridizing colonies (Maniatis et al., 1989) , and inserts sequenced on both strands by the method of dideoxy chain termination using the ABI PRISM dye terminator cycle sequencing kit (PE Applied Biosystems, UK) and 25 ng oligonucleotide primers. Dye labelled products were resolved and detected using the Applied Biosystems DNA sequencer ABI373. Sequence was analysed using the Sequencing Analysis program v3.0.
A 700 bp SmaI fragment from PAC 162-O21 subcloned into pBluescript was con®rmed by sequencing to contain all of exon 1 of the CAVEOLIN-1 gene. This fragment was used to probe Southern blots prepared with genomic DNA from tumours and tumour derived-cell lines for the detection of methylation.
Cell lines
Cell lines listed in Table 1 were cultured in Dulbecco's MEM (Life Technologies) supplemented with 10% FCS (Bioclear UK Ltd., UK).
SSCP analysis
Oligonucleotide primers corresponding to exons 1 (L: AGTTCCCTTAAAGCACAGCC, R: AGAGGCAGA-TAGCAGAAGCG) and 3 (L: CTGTGCTCATGTTG-TGTCAC, R: GAACTTGAAATTGGCACCAGG) of CAVEOLIN-1 were used to perform PCR. One hundred ng of genomic DNA from tumour-derived cell lines, prepared according to a previously described method (Laird et al., 1991) , was used as template. The reaction conditions given above were used, with the addition of 1 mCi [a 32 P]dCTP per reaction. PCR products corresponding to exon 3 were subsequently digested with 5 m HinfI (Life Technologies). 4 ml PCR product was mixed with 8 ml of STOP buer (95% formamide, 200 mM EDTA pH 8.0, 0.01% (w/v) xylene cyanol and bromophenol blue) and denatured by heating at 948C for 10 min. Three ml was then resolved in a 6% nondenaturing polyacrylamide gel containing 5% glycerol. Gels were ®xed by heating at 808C under vacuum, and exposed directly to X-ray ®lm for detection by autoradiography.
Detection of methylation
Ten mg of genomic DNA from 26 primary ovarian tumours isolated as above and from our panel of tumour-derived cell lines was digested with 10 m each of EcoRV and HindIII and then with either 10 m of HpaII or MspI (Life Technologies) and resolved by electrophoresis on a 1% agarose gel. Subsequently, DNA was transferred onto Hybond N+ nylon membrane (Amersham International plc, UK) according to the manufacturer's instructions. Genomic DNA blots were pre-hybridized, probed and visualized as above, using a 700 bp SmaI fragment containing exon 1 of CAVEOLIN-1.
RT ± PCR analysis
Extraction of total RNA from cell lines was carried out following the manufacturer's protocol for Trizol (Life Technologies, UK). One mg of total RNA was used as a template for the synthesis of ®rst strand cDNA by reverse transcription with random hexamers using the GeneAmp RNA PCR core kit (Perkin Elmer, USA) also according to the manufacturer's instructions. One twentieth of the reverse transcription reaction was then subjected to PCR employing the above reaction conditions with 1 mM each of the oligonucleotide primers L: CATGTCTGGGGGCAAA-TACG and R: GAACTTGAAATTGGCACCAGG, which will amplify the entire open reading frame of CAVEOLIN-1. Fifty nM primers (L: ACCACAGTCCATGCCATCAC; R: TCCACCACCCTGTTGCTGTA) which amplify an approximately 500 bp product from house-keeping gene G3PDH cDNA were included as an internal control for ampli®cation eciency. RT ± PCR products were analysed on a 2% agarose gel as above.
Protein extraction and Western blot analysis
Whole cell lysates were prepared in extraction buer (20 mM MES, 150 mM NaCl, 1% Triton, 0.1% SDS, 1 mM PMSF, 2 mM benzamidine). Twenty mg of protein was fractionated by SDS ± PAGE on a 12% acrylamide gel, transferred onto Immobilon P membrane (Millipore UK Ltd., UK) using a semi-dry blotter, and probed using a 1 : 8000 dilution of an anti-caveolin-1 polyclonal antibody (C13630) (Transduction Laboratories, Inc., USA). Following incubation with a 1 : 3000 dilution of a horseradish peroxidase conjugated anti-rabbit Ig secondary antibody (Amersham International, plc., UK), proteins were visualized using enhanced chemiluminescence (Amersham International plc.).
Immunohistochemical detection of Caveolin-1 in breast tissue
Ten specimens of normal breast from reduction mammoplasties and ten primary invasive breast carcinomas were labelled for Caveolin-1 expression by an indirect peroxidase immunohistochemical method using the polyclonal anti-caveolin antibody above. Tissues were snap frozen and stored in liquid nitrogen and 5 mm cryostat sections were cut onto 3-aminopropyl-triethoxysilane treated slides. Immunohistochemistry was performed in humidi®ed chambers at 228C and antibodies were diluted in and slides washed in PBS (10 mM sodium phosphate, 140 mM sodium chloride pH 7.4). Sections were ®xed in absolute acetone for 10 min and washed through three changes of PBS before a solution containing 25% normal human serum and 25% normal swine serum was applied for 10 min to reduce non-speci®c binding. This was replaced by the primary antibody (1 mg/ml in 10% human serum, 10% swine serum). After a 2 h incubation, the sections were washed (365 min) and the secondary antibody (peroxidase conjugated swine anti-rabbit Ig; Dako Ltd, UK) was applied at 1 : 50 in 10% of each serum type for 30 min. After three further 5 min washes, the peroxidase signal was developed by exposure to 0.025% diaminobenzidine tetrahydrochloride, 0.07% NiCl 2 .6H 2 O, 0.01% H 2 O 2 for 10 min producing a black precipitate in positive cells. Sections were counterstained red with safranin, dehydrated through conventional solutions and mounted in DPX. Parallel negative control sections were processed by replacing the primary antibody with an equal concentration of non-immune rabbit immunoglobulin.
A number of breast carcinoma samples ®xed in formalin and embedded in paran were also examined for Caveolin-1 expression. These samples included two biopsy specimens from cancers identi®ed from their histopathology as being myoepithelial in origin. Paran was extracted and sections rehydrated using a standard protocol. Sections were then microwaved at full power in 0.05 M citrate buer (pH 6.0) for 12 min, before being immunochemically stained as above.
